Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine

Allergy and Asthma Proceedings

Volumn 32, Issue 4, 2011, Pages 288-294

  Phillips, Joshua F ^a   Lockey, Richard F ^b   Fox, Roger W ^b   Ledford, Dennis K ^b   Glaum, Mark C ^b  

^a Mississippi Asthma and Allergy Clinic   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; GLUCOCORTICOID; HOUSE DUST ALLERGEN;

ABDOMINAL PAIN; ADULT; ALLERGIC RHINITIS; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; COCKROACH; CONGESTION; COUGHING; DANDER; DIAPHORESIS; DIZZINESS; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; FEMALE; FLUSHING; HEADACHE; HOARSENESS; HUMAN; HYMENOPTERA; HYPOTENSION; IMMUNOTHERAPY; INJECTION SITE PRURITUS; MALE; MOULD; NASAL PRURITUS; NAUSEA; NURSE; POLLEN; PRURITUS; RASH; RED EYE; RETROSPECTIVE STUDY; RHINORRHEA; SEIZURE; SIDE EFFECT; SNEEZING; STRIDOR; SUBCUTANEOUS ALLERGEN IMMUNOTHERAPY; TACHYCARDIA; THORAX DRAINAGE; THORAX PAIN; THROAT TIGHTNESS; TREATMENT RESPONSE; URTICARIA; VOICE CHANGE; WHEEZING; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; ADULT; ALLERGENS; ANAPHYLAXIS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; EPINEPHRINE; FEMALE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79960736551     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3446     Document Type: Article

References (16)

1. Abramson M, Puy R, and Weiner J. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 4:CD001186, 2003.
2. Bousquet J, Lockey R, and Maling H. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102:558-562, 1998.
3. Cox L, Li J, Nelson H, and Lockey R. Allergen immunotherapy: A practice parameter second update. J Allergy Clin Immunol 120:S25-S85, 2007. (Pubitemid 47313519)
4. Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J Allergy Clin Immunol 109:251-256, 2002. (Pubitemid 34158289)
5. Des Roches A, Paradis L, Menardo JL, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 99:450-453, 1997. (Pubitemid 27173080)
6. Noon L. Prophylactic inoculation against hay fever. Lancet 1:1572-1573, 1911.
7. Freeman J. Further observations of the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 2:814-817, 1911.
8. Cox L, Larenas-Linneman D, Lockey R, and Passalacqua G. Speaking the same language. World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 125:569-574, 2010.
9. Stewart G, and Lockey R. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 90:567-578, 1992.
10. Tinkelman D, Cole W, and Tunno J. Immunotherapy: A oneyear prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 95:8-14, 1995.
11. Louit A, and Grammer L. A Retrospective review and analysis of systemic reactions among subcutaneous aeroallergen immunotherapy patients. J Allergy Clin Immunol 123:S60, 2009.
12. Roy S, Sigmon J, Olivier J, et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann Allergy Asthma Immunol 99:82-86, 2007. (Pubitemid 47075956)
13. Confino-Cohen R, and Goldberg A. Allergen immunotherapy-induced biphasic systemic reactions: Incidence, characteristics, and outcome: A prospective study. Ann Allergy Asthma Immunol 104:73-78, 2010.
14. Scranton S, Gonzalez E, and Waibel K. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol 123:493-498, 2009.
15. Kemp S, Lockey R, and Simons F. World Allergy Organization ad hoc committee on epinephrine in anaphylaxis. Epinephrine: The drug of choice for anaphylaxis: A statement of the World Allergy Organization. Allergy 63:1061-1070, 2008.
16. Bock S, Munoz-Furlong A, and Sampson H. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 107: 191-193, 2001. (Pubitemid 32105265)